Skip to main content

Syndax Pharmaceuticals Inc 10-Q for FY2026 Q3

Syndax Pharmaceuticals Inc (SNDX)

10-Q 2026-11-02 For: 2026-09-30
View Original
Added on November 02, 2026

About this 10-Q

Syndax Pharmaceuticals Inc filed this 10-Q on November 2, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Syndax reported third-quarter Revuforj net revenue of $60.7 million, up 90%, and Niktimvo net revenue of $67.4 million, up 47%. MAXPIRe missed its primary endpoint in IPF, and Syndax does not plan to move forward with further axatilimab development there. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$83.3M
up 81.6% from $45.87M a year earlier
Net loss
$49.43M
compared with a net loss of $60.72M a year earlier
Diluted EPS
-$0.55
compared with -$0.70 a year earlier